GlassScriptPhysician profile
Ann S Harada
NPI 1801843842
$26,224.94
in general payments reported to CMS, 2019-2025
38 companies · $4,326 in 2025
The $4,326 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,418 · 2020: $3,353 · 2021: $3,863 · 2022: $4,420 · 2023: $3,437 · 2024: $4,407 · 2025: $4,326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $39.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,130.45 |
| Education | $39.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,066.74 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $3,517.41 | 2019-2025 | Evenity, Krystexxa, Prolia |
| Novo Nordisk INC | $3,449.73 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $2,603.15 | 2021-2025 | |
| Amarin Pharma, INC. | $2,188.85 | 2019-2023 | |
| Lilly USA, LLC | $1,552.92 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $932.20 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $621.90 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $455.01 | 2021-2023 | Xarelto |
| Esperion Therapeutics, INC. | $412.32 | 2020-2025 | Nexletol |
| Horizon Therapeutics Plc | $251.93 | 2020-2021 | |
| Abbott Laboratories | $246.67 | 2021-2023 | Freestyle Libre 3 |
| Radius Health, INC. | $244.08 | 2020-2023 | Tymlos |
| Abbvie INC. | $226.28 | 2021-2025 | |
| Dexcom, INC. | $200.45 | 2024-2025 | Dexcom G6 Transmitter |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Harada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.